Sinovac Files Annual Report on Form 20-F

12 Apr, 2012, 08:00 ET from Sinovac Biotech Ltd.

BEIJING, April 12, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has filed its 2011 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2011 on April 12, 2012.  The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations section.

The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge.  Requests for a hard copy of the 2011 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing details on the request form.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu) and H1N1 influenza (swine flu), as well as animal rabies vaccine for canines.  In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government stockpiling program.  The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program.  Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot & mouth disease), pneumococcal conjugate, pneumococcal polysaccharides, mumps and rubella.  Sinovac sells its vaccines mainly in China and is exporting selected vaccines to Mongolia, Nepal, and the Philippines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Contact:

Helen Yang/Chris Lee Sinovac Biotech Ltd. Tel:  +86-10-8279-9871/9659 Fax:  +86-10-6296-6910 Email: ir@sinovac.com

Investors Stephanie Carrington The Ruth Group Tel: +1-646-536-7017 Email: scarrington@theruthgroup.com

Media Victoria Aguiar The Ruth Group Tel: +1-646-536-7013 Email: vaguiar@theruthgroup.com

SOURCE Sinovac Biotech Ltd.



RELATED LINKS

http://www.sinovac.com